about
Does central sensitization help explain idiopathic overactive bladder?Validation of a bladder symptom screening tool in women with incontinence due to overactive bladderOxybutynin chloride: alterations in drug delivery and improved therapeutic index.Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot.Benchmarking the use of a rapid response team by surgical services at a tertiary care hospital.Advancements in minimally invasive treatments for female stress urinary incontinence: radiofrequency and bulking agents.Safety and efficacy of a patient-controlled bladder management system for treating urinary retention in men.Improving the tolerability of anticholinergic agents in the treatment of overactive bladder.Stress incontinence injection therapy: what is best for our patients?Mixed incontinence: definitions, outcomes, and interventions.The Q-T interval and antimuscarinic drugs.Pathophysiology of overactive bladder.Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence?Botulinum toxin A in the overactive bladder: current status and future directions.The Burden of Overactive Bladder on US Public HealthExpert Panel Recommendations on Lower Urinary Tract Health of Women Across Their Life Span.Somatic syndromes and chronic pain in women with overactive bladder.Staying at the cutting edge: a review and analysis of evidence reporting and grading; the recommendations of the American Urological Association.Radiofrequency for the treatment of stress urinary incontinence in women.Temporal summation to thermal stimuli is elevated in women with overactive bladder syndrome.Salvage procedures in reconstructive urology.Mixed incontinence: current evidence and future perspectives.Nocturia research: current status and future perspectives.Nocturia: new directions.Contemporary management of the painful bladder: a systematic review.ACP Journal Club. Review: drugs for urgency urinary incontinence improve continence in women.Vaginal approaches to pelvic organ prolapse repair.Obesity and female stress urinary incontinence.Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis.Autologous Pubovaginal Sling for the Treatment of Concomitant Female Urethral Diverticula and Stress Urinary Incontinence.Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.Direct visual internal urethrotomy for isolated, post-urethroplasty strictures: a retrospective analysis.Positive outcomes with first onabotulinumtoxinA treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity.Stress urinary incontinence surgery trends in academic female pelvic medicine and reconstructive surgery urology practice in the setting of the food and drug administration public health notifications.The Impact of Pallidal and Subthalamic Deep Brain Stimulation on Urologic Function in Parkinson's Disease.Pelvic Organ Prolapse Surgery in Academic Female Pelvic Medicine and Reconstructive Surgery Urology Practice in the Setting of the Food and Drug Administration Public Health Notifications.Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction.Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
P50
Q26744440-801FF604-693D-45F1-9E7D-3B4BBDDF4BDEQ34528375-7777E18B-C429-48BB-96BB-E1C1BF07539DQ34588729-751BF531-A848-45FF-BBD2-3A09195C89F6Q34605095-4E46448C-8EF3-414F-8180-201C1188C6CDQ35158929-D59E8D68-C350-4DC2-984C-5CCCCBD7106FQ35538009-F0C34AA3-07F7-4229-B4DC-53B1BD8CD972Q36161744-2C9D1353-12C5-4C47-8DF1-474735C24AD4Q36166331-4D5B8DEE-1BBD-42F0-A33A-17369E3ED103Q36238828-4D6E8687-E9BD-42C9-BEE9-30A6EBA908B0Q36277077-79228BCE-977A-4229-BEE2-FE1B4240BDF2Q36292396-757B02B6-DE0F-4D47-BC70-48D76A0C0ED5Q36399000-47FC9F42-B5F7-4BD8-A773-3EA0AD76632EQ36628776-A1DDB4F3-2E3A-4616-ACE6-0708245FBD2CQ36741471-AB0B3683-7B90-4D6C-968D-CD2D33D2492BQ36767014-1EFF8086-4342-41B5-A374-5885DDB1C956Q37424934-DE727353-3BED-4B97-A2FD-EA259B92E2CCQ37547749-BB95EC34-D219-4404-892A-E139F4F937FCQ37554698-5802A7FD-9DF2-4CF3-830B-D015F6FA6310Q37587454-242A3AD3-FBC3-4FD9-8E2B-387F3A3F334CQ37594939-E1E46004-7693-4378-9019-9E064E290848Q37711577-990CB7CB-DFD7-4C7E-AB7C-18BCFCFD8F10Q37739966-ADFE93D0-A220-4CAA-957D-F02FFDE4F476Q37739968-0D9E0860-0978-4759-A9D5-433059C16503Q37887647-FFB7AB4B-5FAA-4E3C-B4CC-3D6CA6235DC0Q37932774-01175F00-64F5-4DDE-AA25-79696EFB2FDBQ38052442-F85F17A9-8505-4418-9DCF-04C5AEFD9917Q38105886-2F2FE5F9-5620-46C7-84B8-3C4FF8757C3BQ38131089-A4E5AD83-D457-4152-942F-7A3956E67104Q38159062-8A1A6054-D226-4621-859C-F4F558D89248Q38534598-F7177D05-36D6-45DB-9089-7DAFC1E997F1Q38731392-71EC78BE-6D6A-41E6-A9A4-827743722D04Q38959080-1D9F769C-C054-4C67-B68A-98CA8BB5FFE9Q38990447-37B017C1-DABA-4A3D-B0BB-1300148CAF2EQ39557915-328F3D9B-CA22-47CA-946D-81D32E222C0CQ39771710-EE9EEA4E-D19C-4B42-AEB5-D027337BE3E9Q40024419-DDFD821B-3E95-4A50-8EAF-0F3069E52542Q40274618-C9CD723C-4F99-4635-A3A3-80C7E5F6EFBCQ40396478-2EE826F1-153D-4780-8687-3F7C12027CDCQ43164201-475DA1D2-42BC-467B-8B7A-96F0DB5F8C89Q43186897-65D5B267-8A12-4FB1-BB68-C55FDB7B8401
P50
name
Roger Dmochowski
@en
type
label
Roger Dmochowski
@en
prefLabel
Roger Dmochowski
@en